Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Rao, C.; Janakiram, N.; Madka, V.; Kumar, G.; Scott, E.; Pathuri, G.; Bryant, T.; Kutche, H.; Zhang, Y.; Biddick, L.; Gali, H.; Zhao, Y.; Lightfoot, S.; Mohammed, A.
    Small-molecule inhibition of GCNT3 disrupts mucin biosynthesis and malignant cellular behaviors in pancreatic cancer (2016), Cancer Res., 76, 1965-1974.
    View publication on PubMed

Cloned(Commentary)

EC Number Cloned (Comment) Organism
2.4.1.102 gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis Homo sapiens
2.4.1.102 gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis Mus musculus

Protein Variants

EC Number Protein Variants Comment Organism
2.4.1.102 additional information p48Cre/+-LSL-KrasG12D+þ GEM with Kras mutations display significant dysregulation of EGF receptor and upregulation of mucin biosynthesis in PanIN lesions and pancreatic ductal adenocarcinoma, genotyping Mus musculus

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.4.1.102 talniflumate selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview Homo sapiens
2.4.1.102 talniflumate selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview Mus musculus

Organism

EC Number Organism UniProt Comment Textmining
2.4.1.102 Homo sapiens O95395
-
-
2.4.1.102 Mus musculus Q5JCT0 LSL-KrasG12D/+ and p48Cre/+ mice
-
2.4.1.102 Mus musculus C57BL/6 Q5JCT0 LSL-KrasG12D/+ and p48Cre/+ mice
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
2.4.1.102 BxPC-3 cell
-
 Homo sapiens
-
2.4.1.102 MiaPaCa cell
-
 Homo sapiens
-
2.4.1.102 additional information human pancreatic cancer tissue array consisting of 90 cases of tumor and matched normal adjacent tissue with survival data, overview Homo sapiens
-
2.4.1.102 additional information transcriptome analysis in pacreatic carcinomas and healthy tissues Mus musculus
-
2.4.1.102 PANC-1 cell
-
 Homo sapiens
-
2.4.1.102 pancreas
-
 Homo sapiens
-
2.4.1.102 pancreas
-
 Mus musculus
-
2.4.1.102 pancreatic cancer cell
-
 Homo sapiens
-
2.4.1.102 pancreatic cancer cell genetically engineered Kras-driven mouse pancreatic tumors Mus musculus
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.4.1.102 UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
-
 Homo sapiens UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
 ?
2.4.1.102 UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
-
 Mus musculus UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
 ?
2.4.1.102 UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
-
 Mus musculus C57BL/6 UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
 ?

Synonyms

EC Number Synonyms Comment Organism
2.4.1.102 core 2 beta-1,6 N-acetylglucosaminyltransferase
-
 Homo sapiens
2.4.1.102 core 2 beta-1,6 N-acetylglucosaminyltransferase
-
 Mus musculus
2.4.1.102 gcnt3
-
 Homo sapiens
2.4.1.102 gcnt3
-
 Mus musculus

Expression

EC Number Organism Comment Expression
2.4.1.102 Homo sapiens inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro down
2.4.1.102 Mus musculus inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro down

General Information

EC Number General Information Comment Organism
2.4.1.102 malfunction aberrant GCNT3 expression is associated with increased mucin production, aggressive tumorigenesis, and reduced patient survival, and CRISPR-mediated knockout of GCNT3 in pancreatic cancer cells reduces proliferation and spheroid formation. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro Homo sapiens
2.4.1.102 malfunction in mouse pancreatic cancer tumors, GCNT3 103fold upregulation is correlated with increased expression of mucins by 5-87fold. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. CRISPR GCNT3-KO leads to reduced cell viability and spheroid formation Mus musculus
2.4.1.102 physiological function the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis Mus musculus
2.4.1.102 physiological function the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis. Correlation between GCNT3 expression and patient survival in human pancreatic cancer Homo sapiens